Melih UÇMAK, Sinem ENGİNLER, Mehmet GÜNDÜZ, İsmail KIRŞAN, Kıvılcım SÖNMEZ

Treatment of Feline Mammary Fibroepithelial Hyperplasia with the Combination of Aglepristone and Cabergoline

A case of fibroepithelial mammary hyperplasia in a two years old, intact, tabby female cat that showed oestrus 1 month ago was treated with the combination of aglepristone (Alizine, Virbac®) and cabergoline (Galastop, Ceva®) administrations. On the day of treatment, serum progesterone concentration was detected as 2,96 ng/ml and serum oestradiol concentration was below 5,0 pg/ml. The cat was treated with subcutaneous (SC) injections of aglepristone (Alizine, Virbac®) 15 mg/kg body weight (b.w.) on two subsequent days per week for three weeks and 5 µg/kg b.w per a day, per os (PO) cabergoline (Galastop, Ceva®) administration was accompanied to this treatment on the first week for seven days. On the examination at the end of the third week, there was a marked regression of the mammary glands and the milk secretion ceased. Six weeks after the initiation of treatment, mammary glands were completely regressed and serum progesterone and oestradiol concentrations were 0.142 ng/ml, and <5pg/ml respectively. It is determined that in such cases which is associated with milk secretion, successful results can be achieved by using aglepristone (Alizine, Virbac®) and cabergoline (Galastop, Ceva®) together. Key Words: Fibroepithelial hyperplasia, aglepristone, cabergoline

Anahtar Kelimeler:

Fibroepitelyal hiperplazi, aglepriston, cabergolin

PDF

___

Allen, H., 1973. Feline mammary hypertrophy. Veterinary Pathology 10, 501-508.
Arbeiter, K., Brass, W., Ballabio, R., Jöchle, W., 1998. Treatment of pseudopregnancy in the bitch with cabergoline, an ergoline derivate. Journal of Small Animal Practice 29, 781-788.
Baştan, A., Fındık, M., Erünal, N., Aslan, S., Kılıçoğlu, Ç., 1998. The use of cabergoline for the treatment of pseudopregnancy in dogs with the purpose of suppressing lactation. Reproduction in Domestic Animal 33,49-53.
Baştan, A., Özenç, E . , Yağcı, İ.P., Beceriklisoy, H.B., 2004. Bir kedide meme hipertrofisi olgusu. Ankara Üniversitesi Veteriner Fakültesi Dergisi 51, 79-82.
Bethlehem, M., Van der I, R.J.T., 1993. Feline fibro- epitheliale hyperplasie bij drie gecastreerde katers na behandeling met progestativa. Tijdschr Diergeneeskd. 118, 650-652.
Treatment of Feline Mammary Fibroepithelial Hyperplasia with the
Görlinger, S., Kooistra, H.S., Van den Broek, A., Okkens, A.C., 2002. Treatment of fibroadenomatous hyperplasia in cats with aglepristone. Journal of Veterinary Internal Medicine 16, 710-713.
Johnston, S.D., Kustritz, M.V.R., Olson, P.N.S., 2001. Mammary hypertropy. In: Johnston, S.D., Kustritz, M.V.R., Olson, P.N.S. (Eds.), Canine and feline theriogenology. Philadelphia, W.B. Saunders Company, pp. 474-477.
Keskin, A., Yılmazbaş, G., Şimşek, G., İntaş, K.S., 2008. Mammary hyperplasia in a pregnant queen. Australian Veterinary Practitoner 38, 75.
Loretti, A.P., Ilha, M.R.S., Breitsameter, I., Faraca, C.S., 2004. Clinical and pathological study of feline mammary fibroadenomatous change associated with depot medroxyprogesterone acetate therapy. Arquivo Brasilero de Medicina Veterinariae Zootecnia. 56(2), 270-274. of Aglepristone and Cabergoline 73
Nak, D., Nak, Y . , İntaş, K.S., Kumru, İ.H., 2004. Treatment of feline mammary fibroadenomatous hyperplasia with aglepristone. Australian Veterinary Practitoner 34(4), 161-162.
Sontas, B.H., Turna, Ö., Uçmak, M., Ekici, H., 2008. What is your diagnosis. Journal of Small Animal Practice 49, 545-547.
Verstegen, J.P., 1998. Pharmacological control of reproduction in the cat. In: England, G., Harvey, M. (Eds.), Manuel of small animal reproduction and neonatology. BSAVA., U.K, pp. 219-226.
Vitasek, R., Dendisova, H., 2006. Treatment of feline fibroepithelial hyperplasia following a single injection of proligestone. Acta Veterinaria Brno 75, 295-297.
Wehrend, A., Hospes, R., Gruber, A.D., 2001. Treatment of feline fibroadenomatous hyperplasia with a progesterone antagonist. Veterinary Record 148, 346-347.